The significant anticancer potential of AA+MD recently described in other GBM cell lines (U87, GS9L) and in vivo GBM models [23,24], together with ongoing clinical studies of PI3K/Akt/mTOR inhibitors, make further investigation of the anticancer potential of the combinations proposed herein reasonable. This evidence concerns the gene AKT1 and glioblastoma.